media – Page 15 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Obtained the drug registration certificate for Quetiapine Fumarate Sustained-Release Tablets

June 15, Huahai Pharmaceutical(600521.SH) announced that the company recently received the “Drug Registration Certificate” for Quetiapine Fumarate Sustained-Release Tablets approved and issued by the State Drug Administration. The drug is used to treat depressive episodes of schizophrenia and bipolar disorder. It was first developed by AstraZeneca and launched in the United States in 2007. According to the data of Minnet, the domestic market sales amount in 2024 will be about 451 million yuan. Huahai Pharmaceutical has invested about 16.93 million yuan in research and development expenses in this project. The approval of this drug further enriches the company’s product line, enhances market competitiveness, and has a positive effect on business development. https://finance.eastmoney.com/a/202506153430842883.html
- Source: drugdu
- 48
- June 17, 2025
China’s first stem cell drug, price set

Recently, the first prescription of Amytosai injection, the first stem cell drug approved for marketing in China, was issued at Peking University People’s Hospital for the treatment of haploid transplant patients. The drug costs 19,800 yuan per treatment, and the total cost is about 158,000 yuan if 8 treatments are considered a complete course of treatment. In comparison with the international market, the U.S. FDA-approved mesenchymal stem cell drug Ryoncil is priced at as high as US$194,000 (about RMB 1.39 million) per dose, which is 70 times the cost of a single dose of Aimitocel injection. The first approved The stem cell therapy Amymatosai Injection (trade name: Ruibosheng) developed by Beijing Bosheng Excellence Biotechnology Co., Ltd. was conditionally approved for marketing by the National Medical Products Administration through the priority review and approval procedure on January 2, 2025. It is indicated for the treatment of acute graft-versus-host disease (aGVHD) in ...
- Source: drugdu
- 71
- June 17, 2025
Winning the Gold Award! Another innovative breakthrough for HEC Pharmaceutical

Recently, the State Intellectual Property Office announced the awarding decision of the 25th China Patent Award. HEC Pharmaceutical’s invention patent “Oseltamivir Phosphate Granules and Preparation Method thereof” (patent number ZL200610066995.7) won the 25th China Patent Gold Award. The China Patent Award is jointly sponsored by the State Intellectual Property Office and the World Intellectual Property Organization. It has nine awards, including the China Patent Gold Award, the China Design Gold Award, and the China Patent Award Best Organization Award. Among them, the gold award project must have a significant level of innovation, outstanding market value and extensive social influence, representing the highest honor in China’s intellectual property field. The award of the invention patent “Oseltamivir Phosphate Granules and Preparation Methods” of East Sunshine Pharmaceutical not only demonstrates the company’s innovative strength in the pharmaceutical field, but also confirms the product’s outstanding performance in terms of technological innovation, clinical value, and ...
- Source: drugdu
- 65
- June 17, 2025
PUBLIC HEALTH

Organiser: ITE Group Time： October 1st – October 3rd, 2025 address：Brovarskiy Avenue 15, Kiev, Ukraine, 02000 Exhibition hall： Kiev International Exhibition Center Product range: Medical Equipment: Diagnostic instruments and devices, X-ray diagnostic equipment, radiation medical devices, medical electromechanical equipment, therapeutic instruments, orthopedic and rehabilitation equipment, hospital and clinic equipment, medical services, sterilization and convalescent equipment, disposable medical supplies and instruments Medical Emergency: Emergency equipment, mobile hospitals, wheelchairs, ambulances Ophthalmology: Ophthalmic equipment, glasses, lenses Dentistry: Dental instruments, equipment, disposable medical products Pharmaceuticals: Intermediates, pharmaceutical products, vaccines, enzymes, homeopathic medicines, mineral and vitamin preparations, hormones, pharmaceutical synthesis products, bioactive additives, pediatric dietary nutrition, chemically synthesized foods, pharmaceutical formulation production equipment, bioresearch About PUBLIC HEALTH： The Ukraine Kiev Medical Equipment Exhibition (PUBLIC HEALTH) aims to provide visitors with the latest technologies and information regarding the pharmaceutical and pharmaceutical industries from Ukraine’s public health sector. This is particularly focused on the use of ...
- Source: drugdu
- 87
- June 17, 2025
Cefazolin Sodium/Sodium Chloride Injection for Injection Obtained Drug Registration Approval

Kelun PharmaceuticalIt was disclosed on the evening of June 12 that the chemical drug “Cefazolin Sodium/Sodium Chloride Injection for Injection” of the company’s subsidiary Hunan Kelun Pharmaceutical Co., Ltd. recently obtained drug registration approval from the State Food and Drug Administration. Disclosures show that cefazolin sodium is a classic drug for anti-infective treatment. It is currently widely used in clinical practice for various perioperative preventive medications and treatment of respiratory tract, skin and soft tissue, bone and joint infections caused by sensitive bacteria. It is also the only cephalosporin recognized by WHO as the preferred choice for surgical prevention. Cefazolin Sodium/Sodium Chloride Injection for Injection is a Class B national medical insurance product. In 2024, sales of cefazolin sodium injection in China will reach 1.35 billion yuan. The Cefazolin Sodium/Sodium Chloride Injection for Injection for which Kelun Pharmaceutical has obtained a drug registration certificate is a powder-liquid double-chamber bag, with ...
- Source: drugdu
- 88
- June 16, 2025
The semaglutide injection project has entered the dose maintenance phase and is expected to be listed in China in 2026

June 12, Hybio Pharmaceutical released the record of investor relations activities. HY3003 is a GLP-1R/GIPR/GCGR triple-target receptor agonist screened by Hanyu Pharmaceuticals and its partners using AI peptide chip technology for weight loss indications. As of this week, the preclinical optimal candidate compound screening and API process development have been completed, and the API pilot scale-up stage has officially begun. In addition to triple-target weight loss drugs, the company also has 1.1-class innovative drugs. HY3000 nasal spray, which is indicated for the prevention of coronavirus infection, is currently in the phase III clinical trial stage. In terms of the exploration of innovative cannabidiol (CBD) drugs , the company has established a partnership with Sinopharm In-depth cooperation is carried out in the fields of research and development of innovative cannabidiol (CBD) drugs , integration of peptide and small nucleic acid drug technologies, and commercial promotion. In terms of clinical progress, the ...
- Source: drugdu
- 78
- June 16, 2025
Sailon’s wholly-owned subsidiary obtains famotidine injection registration certificate

On June 12, Sailon (002898) announced that its wholly-owned subsidiary Hunan Sailon Pharmaceutical (Changsha) Co., Ltd. recently obtained the Drug Registration Certificate for Famotidine Injection approved and issued by the State Drug Administration. The drug is a Class 3 chemical drug, with an injection form and specifications of 1ml: 10mg and 2ml: 20mg. The registration certificate number is 2025S01758/2025S01757, and it is valid until June 9, 2030. Famotidine injection is listed as a national basic medical insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2024)” Class A drugs, mainly used to treat upper gastrointestinal bleeding caused by peptic ulcer. The approval of the drug will further enrich the company’s preparation varieties, but the specific sales situation is still affected by a variety of internal and external environmental factors, and there is a certain degree of uncertainty. In the first quarter of 2025, Sailon achieved revenue of 54.09 million yuan ...
- Source: drugdu
- 66
- June 16, 2025
Eli Lilly’s multi-dose prefilled pen for telportin injection is launched in China

June 12th, Eli Lilly announced that Mufengda (multi-dose prefilled pen for tilpotide injection) is available in China. This is a new injection device launched by Eli Lilly after the successful launch of tilpotide at the beginning of the year . Tilpotide injection is the world’s first and currently the only once-weekly glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist approved for T2DM and long-term weight management. The launch of the multi-dose prefilled pen is to increase supply in China and meet the needs of more patients. 网址：https://finance.eastmoney.com/a/202506123428962957.html
- Source: drugdu
- 108
- June 16, 2025
【EXPERT Q&A】What are the mandatory certifications for product exports to the Middle East?

Drugdu.com expert’s response: I. Saudi Arabia SASO Certification: This certification involves pre-shipment inspection and conformity verification for products imported into the Saudi market, ensuring that imported goods comply with Saudi quality standards. SABER Certification: A system introduced by Saudi Arabia for online application of customs clearance certificates. It is used for product registration, issuance, and obtaining Certificates of Conformity (COC). SABER certification includes a Product Certificate (PC) and a Shipment Certificate (SC). All goods exported to Saudi Arabia must apply for an SC through the SABER system before the goods arrive at the port. II. Gulf Cooperation Council (GCC) Countries GCC Certification (G-MARK Certification): Applicable to the six Gulf countries, including Saudi Arabia, the United Arab Emirates, and Kuwait. It requires products to comply with the unified Gulf Standards (GSO). Products such as low-voltage equipment, toys, and building materials are involved, and they need to pass tests conducted by GSO-authorized ...
- Source: drugdu
- 98
- June 16, 2025
【EXPERT Q&A】What is the effect of rukang saltuzumab on EGFR-mutated lung cancer?

Drugdu.com expert’s response: I. Clinical Research Data KL264-01 Study: In the subgroup analysis targeting EGFR-mutated non-small cell lung cancer (NSCLC) patients, the objective response rate (ORR) of sacituzumab tirumotecan as a monotherapy reached as high as 55%, with a median progression-free survival (PFS) of 11.1 months. These results were significantly superior to those in EGFR wild-type patients, who had an ORR of 24% and a median PFS of 5.3 months. SKB264-II-08 Study: Among 64 previously treated EGFR-mutated NSCLC patients, sacituzumab tirumotecan achieved an ORR of 34%, a disease control rate (DCR) of 84%, a median duration of response (DOR) of 9.6 months, a median PFS of 9.3 months, and a 1-year overall survival (OS) rate of 79%. OptiTROP-Lung03 Study: The sacituzumab tirumotecan group demonstrated a confirmed ORR of 45.1%, significantly higher than the 15.6% in the docetaxel group. The median PFS was 6.9 months, significantly longer than the 2.8 months ...
- Source: drugdu
- 102
- June 13, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.